{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:43:22Z","timestamp":1793965402184,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Pseudomonas<\/jats:italic> infections are among the most common infections encountered in hospitalized patients, especially those with chronic illnesses or an immunocompromised state. Management of these infections has become challenging due to increased antibiotic resistance. Therefore, this study examines the antibiotic resistance profiles of <jats:italic>Pseudomonas<\/jats:italic> spp. and the associated factors among patients admitted to a large tertiary hospital in a developing country.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective observational chart review study assessed patients admitted to a large tertiary hospital in a developing country with a positive culture growth of <jats:italic>Pseudomonas<\/jats:italic> from anybody site. Antibiotic susceptibility of the isolated <jats:italic>Pseudomonas<\/jats:italic> and patient characteristics were studied from the start of 2021 to the end of 2022. The study ground consisted of 185 patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 185 patients with positive <jats:italic>Pseudomonas<\/jats:italic> isolates. Males constituted 54.6% of the sample, while 45.4% were females. The median age of the patients was 53 years. Patient comorbidities and risk factors for <jats:italic>Pseudomonas<\/jats:italic> infection and multidrug resistance were assessed. Antibiotic resistance to the <jats:italic>Pseudomonas<\/jats:italic> regimens showed the highest resistance to meropenem and ciprofloxacin (23.4%, similarly) among isolates of <jats:italic>Pseudomonas aeruginosa<\/jats:italic>. Multidrug resistance (MDR) was found in 108 (58.4%) isolates. The most commonly used antibiotic for treatment was piperacillin-tazobactam, accounting for 33.3% of cases, followed by aminoglycosides at 26.6%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p><jats:italic>Pseudomonas aeruginosa<\/jats:italic> isolates were resistant to meropenem and ciprofloxacin. Over half of the isolates were multidrug-resistant, which was worrying. Piperacillin-tazobactam and aminoglycosides were the most often utilized antibiotics, highlighting the significance of susceptibility testing. Implementing antimicrobial stewardship programs and infection control measures can help reduce drug resistance and improve outcomes in <jats:italic>Pseudomonas<\/jats:italic> infections.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13756-023-01355-4","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T18:01:59Z","timestamp":1703095319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antibiotic resistance profiles and associated factors of Pseudomonas Infections among patients admitted to large tertiary care hospital from a developing country"],"prefix":"10.1186","volume":"12","author":[{"given":"Sara","family":"Shbaita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa","family":"Abatli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoun W.","family":"Sweileh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banan M","family":"Aiesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Sabateen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam T.","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adham","family":"AbuTaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u2019ed H.","family":"Zyoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"issue":"1","key":"1355_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1099\/mic.0.000860","volume":"166","author":"SP Diggle","year":"2020","unstructured":"Diggle SP, Whiteley M. Microbe Profile: Pseudomonas aeruginosa: opportunistic pathogen and lab rat. Microbiol (Reading). 2020;166(1):30\u20133.","journal-title":"Microbiol (Reading)"},{"key":"1355_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fcimb.2017.00039","volume":"7","author":"MF Moradali","year":"2017","unstructured":"Moradali MF, Ghods S, Rehm BH. Pseudomonas aeruginosa Lifestyle: a paradigm for Adaptation, Survival, and persistence. Front Cell Infect Microbiol. 2017;7:39.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"1355_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41392-022-01056-1","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, Liang H, Song X, Wu M. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther. 2022;7(1):199.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"1355_CR4","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1513\/AnnalsATS.201906-459OC","volume":"18","author":"E Sando","year":"2021","unstructured":"Sando E, Suzuki M, Ishida M, Yaegashi M, Aoshima M, Ariyoshi K, Morimoto K. Definitive and indeterminate Pseudomonas aeruginosa Infection in adults with community-acquired Pneumonia: a prospective observational study. Ann Am Thorac Soc. 2021;18(9):1475\u201381.","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"1355_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ijid.2005.06.013","volume":"10","author":"HH Balkhy","year":"2006","unstructured":"Balkhy HH, Cunningham G, Chew FK, Francis C, Al Nakhli DJ, Almuneef MA, Memish ZA. Hospital- and community-acquired Infections: a point prevalence and risk factors survey in a tertiary care center in Saudi Arabia. Int J Infect Dis. 2006;10(4):326\u201333.","journal-title":"Int J Infect Dis"},{"key":"1355_CR6","doi-asserted-by":"crossref","unstructured":"Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, Faverio P, Cilloniz C, Rodriguez-Cintron W, Aliberti S. Burden and risk factors for Pseudomonas aeruginosa community-acquired Pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J 2018, 52(2).","DOI":"10.1183\/13993003.01190-2017"},{"issue":"18","key":"1355_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","volume":"81","author":"D Reynolds","year":"2021","unstructured":"Reynolds D, Kollef M. The epidemiology and Pathogenesis and treatment of Pseudomonas aeruginosa Infections: an update. Drugs. 2021;81(18):2117\u201331.","journal-title":"Drugs"},{"issue":"4","key":"1355_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/tropicalmed8040205","volume":"8","author":"TA Hafiz","year":"2023","unstructured":"Hafiz TA, Bin Essa EA, Alharbi SR, Alyami AS, Alkudmani ZS, Mubaraki MA, Alturki NA, Alotaibi F. Epidemiological, microbiological, and clinical characteristics of Multi-resistant Pseudomonas aeruginosa isolates in King Fahad Medical City, Riyadh, Saudi Arabia. Trop Med Infect Disease. 2023;8(4):205.","journal-title":"Trop Med Infect Disease"},{"issue":"6","key":"1355_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/cc10425","volume":"15","author":"L Pagani","year":"2011","unstructured":"Pagani L, Afshari A, Harbarth S. Year in review 2010: critical care\u2013Infection. Crit Care. 2011;15(6):238.","journal-title":"Crit Care"},{"issue":"1","key":"1355_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","volume":"92","author":"HS Sader","year":"2018","unstructured":"Sader HS, Castanheira M, Duncan LR, Flamm RK. Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States Medical centers stratified by Infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015\u20132016. Diagn Microbiol Infect Dis. 2018;92(1):69\u201374.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"1355_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and Tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1355_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhin.2019.06.005","volume":"103","author":"YP Tabak","year":"2019","unstructured":"Tabak YP, Merchant S, Ye G, Vankeepuram L, Gupta V, Kurtz SG, Puzniak LA. Incremental clinical and economic burden of suspected Respiratory Infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States. J Hosp Infect. 2019;103(2):134\u201341.","journal-title":"J Hosp Infect"},{"key":"1355_CR13","doi-asserted-by":"crossref","unstructured":"Hafiz TA, Bin Essa EA, Alharbi SR, Alyami AS, Alkudmani ZS, Mubaraki MA, Alturki NA, Alotaibi F. Epidemiological, microbiological, and clinical characteristics of Multi-resistant Pseudomonas aeruginosa isolates in King Fahad Medical City, Riyadh, Saudi Arabia. Trop Med Infect Dis 2023, 8(4).","DOI":"10.3390\/tropicalmed8040205"},{"issue":"1","key":"1355_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jiph.2020.11.010","volume":"14","author":"FA Alhussain","year":"2021","unstructured":"Alhussain FA, Yenugadhati N, Al Eidan FA, Al Johani S, Badri M. Risk factors, antimicrobial susceptibility pattern and patient outcomes of Pseudomonas aeruginosa Infection: a matched case-control study. J Infect Public Health. 2021;14(1):152\u20137.","journal-title":"J Infect Public Health"},{"issue":"5","key":"1355_CR15","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1128\/IAI.01652-14","volume":"82","author":"SJ Cole","year":"2014","unstructured":"Cole SJ, Records AR, Orr MW, Linden SB, Lee VT. Catheter-associated urinary tract Infection by Pseudomonas aeruginosa is mediated by exopolysaccharide-independent biofilms. Infect Immun. 2014;82(5):2048\u201358.","journal-title":"Infect Immun"},{"issue":"3","key":"1355_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/pathogens11030300","volume":"11","author":"FF Tuon","year":"2022","unstructured":"Tuon FF, Dantas LR, Suss PH, Tasca Ribeiro VS. Pathogenesis of the Pseudomonas aeruginosa biofilm: a review. Pathogens. 2022;11(3):300.","journal-title":"Pathogens"},{"issue":"15","key":"1355_CR17","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","volume":"323","author":"JL Vincent","year":"2020","unstructured":"Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, Finfer S, Pelosi P, Brazzi L, Aditianingsih D, et al. Prevalence and outcomes of Infection among patients in Intensive Care Units in 2017. JAMA. 2020;323(15):1478\u201387.","journal-title":"JAMA"},{"key":"1355_CR18","doi-asserted-by":"crossref","unstructured":"Ribeiro \u00c1CdS, Crozatti MTL, Silva AAd, Macedo RS. Machado AMdO, Silva ATdA: Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption. Rev Soc Bras Med Trop 2019, 53.","DOI":"10.1590\/0037-8682-0498-2018"},{"issue":"4","key":"1355_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/archinte.160.4.501","volume":"160","author":"I Chatzinikolaou","year":"2000","unstructured":"Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med. 2000;160(4):501\u20139.","journal-title":"Arch Intern Med"},{"issue":"3","key":"1355_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/MRM.0000000000000271","volume":"32","author":"AM Spagnolo","year":"2021","unstructured":"Spagnolo AM, Sartini M, Cristina ML. Pseudomonas aeruginosa in the healthcare facility setting. Reviews and Research in Medical Microbiology. 2021;32(3):169\u201375.","journal-title":"Reviews and Research in Medical Microbiology"},{"issue":"252","key":"1355_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.31729\/jnma.6517","volume":"60","author":"N Maharjan","year":"2022","unstructured":"Maharjan N. Pseudomonas aeruginosa isolates among clinical samples showing growth in a Tertiary Care Centre: a descriptive cross-sectional study. JNMA J Nepal Med Assoc. 2022;60(252):676\u201380.","journal-title":"JNMA J Nepal Med Assoc"},{"issue":"1","key":"1355_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13756-019-0520-8","volume":"8","author":"Q Shi","year":"2019","unstructured":"Shi Q, Huang C, Xiao T, Wu Z, Xiao Y. A retrospective analysis of Pseudomonas aeruginosa bloodstream Infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible Infections. Antimicrob Resist Infect Control. 2019;8(1):68.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"1355_CR23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ajic.2005.11.010","volume":"34","author":"G Yetkin","year":"2006","unstructured":"Yetkin G, Otlu B, Cicek A, Kuzucu C, Durmaz R. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa Infections in a University Hospital, Malatya, Turkey. Am J Infect Control. 2006;34(4):188\u201392.","journal-title":"Am J Infect Control"},{"issue":"8","key":"1355_CR24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3201\/eid1408.070751","volume":"14","author":"RK Gupta","year":"2008","unstructured":"Gupta RK, George R, Nguyen-Van-Tam JS. Bacterial Pneumonia and pandemic Influenza planning. Emerg Infect Dis. 2008;14(8):1187.","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"1355_CR25","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.tim.2021.03.018","volume":"29","author":"LF Westblade","year":"2021","unstructured":"Westblade LF, Simon MS, Satlin MJ. Bacterial coinfections in coronavirus Disease 2019. Trends Microbiol. 2021;29(10):930\u201341.","journal-title":"Trends Microbiol"},{"issue":"4","key":"1355_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jhin.2009.04.020","volume":"73","author":"KG Kerr","year":"2009","unstructured":"Kerr KG, Snelling AM. Pseudomonas aeruginosa: a formidable and ever-present adversary. J Hosp Infect. 2009;73(4):338\u201344.","journal-title":"J Hosp Infect"},{"issue":"8","key":"1355_CR27","first-page":"7","volume":"6","author":"RS Gupta","year":"2019","unstructured":"Gupta RS, Shrestha N. Clinical significance and antibiogram of Pseudomonas aeruginosa isolated from tertiary care hospital of Birgunj, Nepal. Indian J Med Res Pharm Sci. 2019;6(8):7\u201310.","journal-title":"Indian J Med Res Pharm Sci"},{"issue":"4","key":"1355_CR28","first-page":"398","volume":"127","author":"A Varaiya","year":"2008","unstructured":"Varaiya A, Kulkarni N, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients. Indian J Med Res. 2008;127(4):398\u2013402.","journal-title":"Indian J Med Res"},{"key":"1355_CR29","doi-asserted-by":"publisher","first-page":"e20180498","DOI":"10.1590\/0037-8682-0498-2018","volume":"53","author":"\u00c1CDS Ribeiro","year":"2019","unstructured":"Ribeiro \u00c1CDS, Crozatti MTL, Silva AAD, Macedo RS, Machado AMO, Silva ATA. Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption. Rev Soc Bras Med Trop. 2019;53:e20180498.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"1","key":"1355_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12879-020-05404-w","volume":"20","author":"M Brzozowski","year":"2020","unstructured":"Brzozowski M, Krukowska \u017b, Galant K, Jursa-Kulesza J, Kosik-Bogacka D. Genotypic characterisation and antimicrobial resistance of Pseudomonas aeruginosa strains isolated from patients of different hospitals and medical centres in Poland. BMC Infect Dis. 2020;20(1):693.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1355_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/JALSI\/2016\/29259","volume":"8","author":"G Adwan","year":"2016","unstructured":"Adwan G, Shtayah A, Adwan K, Al-Sheboul S, Othman S. Prevalence and molecular characterization of P. Aeruginosa isolates in the West Bank-Palestine for ESBLs, MBLs and integrons. J Appl Life Sci Int. 2016;8(2):1\u201311.","journal-title":"J Appl Life Sci Int"},{"issue":"1","key":"1355_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12879-022-07114-x","volume":"22","author":"G Arman","year":"2022","unstructured":"Arman G, Zeyad M, Qindah B, Abu Taha A, Amer R, Abutaha S, Koni AA, Zyoud SH. Frequency of microbial isolates and pattern of antimicrobial resistance in patients with hematological malignancies: a cross-sectional study from Palestine. BMC Infect Dis. 2022;22(1):146.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"1355_CR33","first-page":"265","volume":"10","author":"H Saderi","year":"2015","unstructured":"Saderi H, Owlia P. Detection of multidrug resistant (MDR) and extremely drug resistant (XDR) P. Aeruginosa isolated from patients in Tehran, Iran. Iran J Pathol. 2015;10(4):265.","journal-title":"Iran J Pathol"},{"key":"1355_CR34","doi-asserted-by":"crossref","unstructured":"Al-Orphaly M, Hadi HA, Eltayeb FK, Al-Hail H, Samuel BG, Sultan AA, Skariah S. Epidemiology of Multidrug-Resistant Pseudomonas aeruginosa in the Middle East and North Africa Region. mSphere 2021, 6(3).","DOI":"10.1128\/mSphere.00202-21"},{"issue":"6","key":"1355_CR35","first-page":"1622","volume":"35","author":"L Farooq","year":"2019","unstructured":"Farooq L, Memon Z, Ismail MO, Sadiq S. Frequency and antibiogram of multi-drug resistant pseudomonas aeruginosa in a Tertiary Care Hospital of Pakistan. Pakistan J Med Sci. 2019;35(6):1622.","journal-title":"Pakistan J Med Sci"},{"key":"1355_CR36","doi-asserted-by":"crossref","unstructured":"Esiovwa R, Connolly J, Hursthouse A, Mukherji S, Mukherji S, Parasnis A, Sachwani K, Henriquez F. Bridging the gaps in the global governance of antimicrobia l resistance: the UN sustainable development goals and globa l health security agenda [version 1; peer review: 1 approved]. 2022.","DOI":"10.12688\/routledgeopenres.17407.1"},{"issue":"3","key":"1355_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1089\/mdr.2019.0209","volume":"27","author":"Multidrug-Resistant Hospital Bacteria","year":"2021","unstructured":"Multidrug-Resistant Hospital Bacteria. Epidemiological factors and susceptibility Profile. Microb Drug Resist. 2021;27(3):433\u201340.","journal-title":"Microb Drug Resist"},{"issue":"4","key":"1355_CR38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4067\/S0716-10182014000400003","volume":"31","author":"AC Ossa-Giraldo","year":"2014","unstructured":"Ossa-Giraldo AC, Echeverri-Toro LM, Santos ZM, Garc\u00eda MG, Agudelo Y, Ram\u00edrez F, Ospina S. [Risk factors for multidrug-resistant Pseudomonas aeruginosa Infection, in a tertiary hospital in Colombia]. Rev Chil Infectol. 2014;31(4):393\u20139.","journal-title":"Rev Chil Infectol"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-023-01355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-023-01355-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-023-01355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T18:05:29Z","timestamp":1703095529000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-023-01355-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1186\/s13756-023-01355-4","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The <i>Institutional Review Boards (IRBs) of An-Najah National University<\/i> approved the study protocol, and the collected data were only used for clinical research purposes. The information was kept confidential and was not used for any other purpose. Patient information was coded to protect their identities. Since retrospective data were used, the <i>IRB of An-Najah National University<\/i> waived the requirement for informed consent. The authors confirmed that all the methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}